Estimation after subpopulation selection in adaptive seamless trials

Statistics in Medicine

Volumn 34, Issue 18, 2015, Pages 2581-2601

  Kimani, Peter K ^a   Todd, Susan ^b   Stallard, Nigel ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Adaptive seamless designs; Multi arm multi stage trials; Phase II III clinical trials; Subgroup analysis; Subpopulation

Indexed keywords

ADAPTIVE SEAMLESS TRIAL; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; HUMAN; INFORMATION PROCESSING; MATHEMATICAL ANALYSIS; NAIVE POINT ESTIMATOR; POINT ESTIMATION; PREVALENCE; SAMPLING; SELECTION BIAS; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STATISTICAL PARAMETERS; STUDY DESIGN; SUBPOPULATION SELECTION; UNBIASED POINT ESTIMATOR; BIOMETRY; COMPUTER SIMULATION; METHODOLOGY; PATIENT SELECTION; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL BIAS;

BIAS (EPIDEMIOLOGY); BIOMETRY; COMPUTER SIMULATION; HUMANS; PATIENT SELECTION; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84935687765     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6506     Document Type: Article

References (36)

1. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 1955; 50:1096-1121.
2. Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75:303-310.
3. Schaid DJ, Wieand S, Therneau TM. Optimal two-stage screening designs for survival comparison. Biometrika 1990; 77:507-513.
4. Bauer P, Kieser M. Combining different phases in the development of medical treatments within a single trial. Statistics in Medicine 1999; 18:1833-1848.
5. Hommel G. Adaptive modifications of hypotheses after an interim analysis. Biometrical Journal 2001; 43:581-589.
6. Stallard N, Todd S. Sequential designs for phase III clinical trials incorporating treatment selection. Statistics in Medicine 2003; 22:689-703.
7. Posch M, Koenig F, Branson M, Brannath W, Dunger-Baldauf C, Bauer P. Testing and estimation in flexible group sequential designs with adaptive treatment selection. Statistics in Medicine 2005; 24:3697-3714.
8. Bretz F, König F, Racine A, Maurer W. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biometrical Journal 2006; 48:623-634.
9. Kimani PK, Stallard N, Hutton JL. Dose selection in seamless phase II/III clinical trials based on efficacy and safety. Statistics in Medicine 2009; 28:917-936.
10. Kimani PK, Glimm E, Maurer W, Hutton JL, Stallard N. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods. Statistics in Medicine 2012; 31:2068-2085.
11. Cohen A, Sackrowitz HB. Two stage conditionally unbiased estimators of the selected mean. Statistics and Probability Letters 1989; 8:273-278.
12. Shen L. Estimation following selection of the largest of two normal means. Statistics in Medicine 2001; 20:1913-1929.
13. Stallard N, Todd S. Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference 2005; 135:402-419.
14. Bowden J, Glimm E. Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 2008; 50(4): 515-527.
15. Kimani PK, Todd S, Stallard N. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Statistics in Medicine 2013; 32(17): 2893-2910.
16. Wu SS, Wang W, Yang MCK. Interval estimation for drop-the-losers design. Biometrika 2010; 97(2): 405-418.
17. Neal D, Casella G, Yang MCK, Wu SS. Interval estimation in two-stage drop-the-losers clinical trials with flexible treatment selection. Statistics in Medicine 2011; 30:2804-2814.
18. Magirr D, Jaki T, Posch M, Klinglmueller F. Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika 2013; 100:985-996.
19. Kimani PK, Todd S, Stallard N. A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Biometrical Journal 2014; 56(1): 107-128.
20. Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, DONEPEZIL MSAD STUDY INVESTIGATORS GROUP . Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry 2005; 20(6): 559-569.
21. Wheeler M, De-Herdt V, Vonck K, Gilbert K, Manem S, Mackenzie T, Jobst B, Roberts D, P Williamson, Van-Roost D, Boon P, Thadani V. Efficacy of vagus nerve stimulation for refractory epilepsy among patient subgroups: a re-analysis using the engel classification. Seizure 2011; 20:331-335.
22. Amado RG, Wolf M, Peeters M, Van-Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, S Suggs, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008; 26(10): 1626-1634.
23. Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine 2009; 28:1445-1463.
24. Mäkelä KT, Eskelinen A, Paavolainen P, Pulkkinen P, Remes V. Cementless total hip arthroplasty for primary osteoarthritis in patients aged 55years and older. Acta Orthopaedica 2010; 81(1): 42-52.
25. Spiessens B, Debois M. Adjusted significance levels for subgroup analyses in clinical trials. Contemporary Clinical Trials 2010; 31:647-656.
26. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10:1356-1364.
27. Friede T, Parsons N, Stallard N. A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 2012; 31:4309-4320.
28. Stallard N, Hamborg T, Parsons N, Friede T. Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 2014; 24:168-187.
29. Lindgren BW. Statistical Theory 3rdedn. Collier Macmillan International Editions, London, 1976.
30. Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2001; 16:852-857.
31. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Schwam EM, DONEPEZIL MSAD STUDY INVESTIGATORS GROUP . Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry 2001; 57:613-620.
32. Carreras M, Brannath W. Shrinkage estimation in two-stage adaptive designs with mid-trial treatment selection. Statistics in Medicine 2013; 32(10): 1677-1690.
33. Stallard N, Todd S, Whitehead J. Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 2008; 138:1629-1638.
34. Food and drug administration . Guidance for industry: adaptive design clinical trials for drugs and biologics @ONLINE, 2014. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM201790.pdf [Accessed on 5 April 2015].
35. Bauer P, Koenig F, Brannath W, Posch M. Selection and bias - two hostile brothers. Statistics in Medicine 2010; 29:1-13.
36. Todd S, Whitehead J, Facey KM. Point and interval estimation following a sequential clinical trial. Biometrika 1996; 83(2): 453-461.